Pancreatic Disease Center

NCCAM Competing Renewal Submitted on September 12, 2012

PDC — Fri, 07 Dec 2012 21:36:53 +0000

9th Annual Agi Hirshberg Symposium on Pancreatic Cancer. January 26, 2013

PDC — Fri, 07 Dec 2012 21:33:02 +0000

Saturday, January 26, 2013

9:30 a.m. – 2:30 p.m.

UCLA Faculty Center

PROGRAM SCHEDULE FOR PATIENT AND FAMILY SESSION

ADVANCES IN PANCREATIC CANCER MANAGEMENT

9:30 – 9:45 a.m.

Welcome and Opening Remarks

Agi Hirshberg

Founder & CEO

Hirshberg Foundation for Pancreatic Cancer Research

9:45 – 10:00 a.m.

Remarks from the Dean of Medical School

A. Eugene Washington, MD, MSc

Vice Chancellor, Health Sciences & Dean, School of Medicine

10:00 – 10:30 a.m.

Surgical Management

O. Joe Hines, MD

University of California, Los Angeles

10:30 – 11:00 a.m.

Genomic Medicine

Teresa (Teri) Brentnall, MD

University of Washington

11:00 – 11:30 a.m.

Chemotherapeutic Management

Lee Rosen, MD

University of California, Los Angeles

11:30 – 12:00 p.m.

Psychosocial Management

Anne Coscarelli, PhD

University of California, Los Angeles

12:00 – 12:30 p.m.

Cancer Prevention

Diane Harris, PhD, MPH

DHHS Center for Disease Control and Prevention

12:30 – 1:00 p.m.

GENERAL DISCUSSION

1:00 – 2:30 p.m.

LUNCH BREAK

Inhibition of Glycogen Phosphorylation Induces Changes in Cellular Proteom and Signaling Pathways in MIA Pancreatic Cancer Cells

Sydney — Wed, 28 Mar 2012 18:24:59 +0000

Objectives: Novel quantitative proteomic approaches were used to study the effects of inhibition of glycogen phosphorylase on proteome and signaling pathways in MIA PaCa-2 pancreatic cancer cells.

Methods: We performed quantitative proteomic analysis in MIA PaCa-2 cancer cells treated with a stratified dose of CP-320626 (5-chloro-1H-indole-2-carboxylic acid [1-(4-fuorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2 oxoethyl] amide) (25, 50, and 100 μM). The effect of metabolic inhibition on cellular protein turnover dynamics was also studied using the modified SILAC (stable isotope labeling with amino acids in cell culture) method.

Results: A total of 22 protein spots and 4 phosphoprotein spots were quantitatively analyzed. We found that dynamic expression of total proteins and phosphoproteins was significantly changed in MIA PaCa-2 cells treated with an incremental dose of CP-320626. Functional analyses suggested that most of the proteins differentially expressed were in the pathways of mitogen-activated protein kinase/extracellular signal–regulated kinase and tumor necrosis factor α/nuclear factor κB.

Conclusions: Signaling pathways and metabolic pathways share many common cofactors and substrates forming an extended metabolic network. The restriction of substrate through 1 pathway such as inhibition of glycogen phosphorylation induces pervasive metabolomic and proteomic changes manifested in protein synthesis, breakdown, and posttranslational modification of signaling molecules. Our results suggest that quantitative proteomic is an important approach to understand the interaction between metabolism and signaling pathways.

Abbreviations: MALDI – matrix-assisted laser desorption ionization, TOF/TOF MS – time-of-flight/time-of-flight mass spectrometry, 2-DE – 2-dimensional electrophoresis, PMF – peptide mass fingerprinting, CP-320626 – 5-chloro-1H-indole-2-carboxylic acid [1-(4-fuorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2 oxoethyl]amide

Ma, Danjun; Wang, Jiarui; Zhao, Yingchun; Lee, Wai-Nang Paul; Xiao, Jing; Go, Vay Liang W.; Wang, Qi; Recker, Robert R.; Xiao, Gary Guishan

Pancreas. 41(3):397-408, April 2012.

The latest issue of the Pancreas can be found here.

8th Annual Agi Hirshberg Symposium on Pancreatic Cancer. January 31, 2012

Sydney — Wed, 28 Mar 2012 17:40:14 +0000

JANUARY 31, 2012

This year’s meeting was held at the UCLA Faculty Center on January 31, 2012 with the support of the unrestricted educational grants from Amgen, Genetech and Celgene. We had participants from regional and national scientists and physicians as well as patients and family support groups.

The meeting was opened by Ms. Agi Hirshberg, CEO and founder of the Hirshberg Foundation, by reviewing the accomplishments of the Foundation in research, patient care, and education over their fifteen year history. She highlighted the seed grant program in particular, which is now in its 8^th year. It started with 15 national applicants and has since expanded to 44 national and international applications this year.

Many national research programs have received and participated in the seed program and they are listed on the Foundation’s website (www.pancreatic.org). She congratulated this year’s 6 awardees who presented their work at the scientific portion during the morning program.

Dr. Go then thanked Ms. Agi Hirshberg and congratulated her for the success of her seed grant program, but also thanked her and her foundation’s contribution to UCLA’s pancreatic cancer research, clinical practice and education programs. Without the Foundation’s support, we would not have achieved the comprehensive program that now exists at UCLA (pancreas.ucla.edu).

This year’s scientific session was chaired by Dr. Go for the first half and by Dr. Howard Reber during the second half. The invited speakers were the awardees of this year’s Foundation seed grants including Dr. David Gius from Vanderbilt Medical School, Dr. Stephen Kendall from Duke University Medical Center, Dr. Andrea Bullock from Beth Israel Deaconess Medical Center, Dr. Emmanuelle Meuillet from the University of Arizona Cancer Center, Dr. Pamela Itkin-Ansari from the University of California San Diego, and Dr. Yung-Ya Lin from the University of California Los Angeles. The highlights of their presentations are included in this newsletter.

The scientific section was followed by the patient and family session was started with opening remarks given by Dr. A. Eugene Washington, Vice Chancellor of Health Sciences and Dean of the School of Medicine. The invited speakers included Dr. Charles Brunicardi from the UCLA Santa Monica Medical Center, Dr. Diane Simeone from the University of Michigan, Dr. Melbern Wilcox from the University of Alabama at Birmingham, and Dr. Thomas Strouse from the University of California Los Angeles. Their presentations focused on the exciting concepts of pancreatic cancer stem cells, personalized medicine, advances and approaches to endoscopic diagnosis and palliative management of patients with pancreatic cancer. This year’s program also included workshops focused on patient and family support, genetic counseling, and cancer legal resources.

As in previous years, this year’s symposium was enriched by twelve poster presentations conducted by the investigators at the Hirshberg Laboratory for Pancreatic Cancer Research, the UCLA Center for Excellence in Pancreatic Diseases, the VA of Greater Los Angeles Health Care System, the LA BioMed Institution and the Southern California Research Center for Alcoholic Liver and Pancreatic Diseases. The scientific communities and the patients and family support groups are extremely grateful to the Foundation’s continued support to their education and research missions. Congratulations for a very successful symposium.

The full recap can be found here: 8th Annual Agi Hirshberg Symposium Recap